交易中 04-01 12:02:21 美东时间
-1.300
-2.88%
今日重点评级关注:Maxim Group:上调Theriva Biologics评级至"买入",目标价1美元;HC Wainwright & Co.:维持Bicara Therapeutics"买入"评级,目标价从40美元升至42美元
04-01 16:34
Citigroup analyst Paul Diamond maintains Range Resources (NYSE:RRC) with a Neutral and raises the price target from $43 to $50.
04-01 03:34
今日重点评级关注:Guggenheim:维持Cabaletta Bio"买入"评级,目标价从15美元升至16美元;HC Wainwright & Co.:维持Palvella Therapeutics"买入"评级,目标价从255美元升至270美元
03-25 10:31
Stocks drop as surging oil prices and a more hawkish Federal Reserve reignites stagflation fears. Treasury yields climb, gold tumble and energy stocks surge while miners face their steepest losses since 2008.
03-20 01:36
今日重点评级关注:韦德布什:维持Black Diamond Therapeutic"跑赢大市"评级,目标价从13美元升至14美元;花旗:维持Olema Pharmaceuticals"买入"评级,目标价从60美元升至62美元
03-18 10:48
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45
Barclays analyst Betty Jiang maintains Range Resources (NYSE:RRC) with a Equal-Weight and raises the price target from $39 to $41.
03-16 23:28
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday
03-16 18:00
今日重点评级关注:Freedom Capital Markets:维持LifeMD"买入"评级,目标价从8美元升至10美元;Chardan Capital:维持Opus Genetics"买入"评级,目标价从9美元升至11美元
03-13 09:59
今日重点评级关注:韦德布什:维持TScan Therapeutics"跑赢大市"评级,目标价从4美元升至5美元;HC Wainwright & Co.:维持莱斯康制药"买入"评级,目标价从4美元升至6美元
03-06 11:58